Free tool
FAERS Monitor: Akten
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022221 or its brand name (Akten, Lidocaine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
89
Serious
69
78% of reports
Hospitalization
39
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective14
- local anaesthetic systemic toxicity8
- off label use8
- vision blurred8
- visual acuity reduced8
- overdose7
- hypertension6
- product use in unapproved indication6
- eye pain5
- visual impairment5
- vitreous floaters5
- cystoid macular oedema4
- fatigue4
- generalised tonic-clonic seizure4
- hypotension4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 2 |
| 2013 | 4 |
| 2014 | 8 |
| 2015 | 1 |
| 2016 | 5 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 7 |
| 2022 | 4 |
| 2023 | 44 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 4 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,070 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| local anaesthetic systemic toxicitySignal | 8 | 1795.5 | 924.5 | 12,516 |
| cystoid macular oedemaSignal | 4 | 502.8 | 192.7 | 1,530 |
| vitreous floatersSignal | 5 | 120.3 | 51.3 | 478 |
| generalised tonic-clonic seizureSignal | 4 | 57.1 | 21.9 | 168 |
| visual acuity reducedSignal | 8 | 56.9 | 29.4 | 386 |
| eye painSignal | 5 | 20.9 | 8.9 | 76 |
| vision blurredSignal | 8 | 13.8 | 7.1 | 83 |
| visual impairmentSignal | 5 | 9.5 | 4.1 | 30 |
| overdoseSignal | 7 | 7.7 | 3.8 | 35 |
| hypertensionSignal | 6 | 6.7 | 3.1 | 24 |
| product use in unapproved indicationSignal | 6 | 5.7 | 2.6 | 19 |
| hypotensionSignal | 4 | 4.7 | 1.8 | 8 |
| drug ineffectiveSignal | 14 | 2.5 | 1.6 | 12 |
| off label useSignal | 8 | 2.2 | 1.1 | 4 |
| fatigue | 4 | 1.2 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.